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Summary A morphological method has been developed allowing measurement of the effect on intestinal
epithelia of vincristine. In routinely prepared tissue sections the proportion of mitotic events progressing
beyond metaphase is counted by microscopy. When estimated over a range of doses of vincristine this post-
metaphase index (PMI) can be used to compare the sensitivity of differing intact tissues. Intestinal tumours
were induced in rats by chemical carcinogenesis. Administration of vincristine in the presence or absence of
verapamil was performed in these tumour-bearing animals. Sections were prepared from colonic and small-
bowel tumours and from normal mucosa. The results show that verpamil increases the sensitivity of the
tissues studied to vincristine. A dose dependent effect of verapamil on vincristine sensitisation was
demonstrated in colonic tissues. These findings indicate a shared pharmacological property between the
resistance of primary tumour tissue and the multidrug-resistance phenotype.
'Multidrug-resistance' (MDR) to a variety of naturally
occurring agents used in cancer chemotherapy is a major
area of research interest (Ling et al., 1983, Tsuruo, 1983). It
has been shown to contribute to resistance to the Vinca
alkaloids, anthracyclines and podophyllotoxins. Vincristine is
one of the few drugs with any role in the chemotherapy of
colonic carcinoma. The problem of primary resistance to this
drug has severely limited its usefulness and deserves in-
vestigation. We are currently interested in the possible
similarity, in terms of the underlying biochemical processes
responsible, between this primary resistance phenomenon
and MDR. Studies using cell lines of this latter acquired
form of resistance demonstrate that many lipophilic drugs
are able to abolish or reduce it (Skovsgaard et al., 1984).
The postulated mechanisms include an interaction with the
cell plasma membrane, the site of a putative drug-
elimination pathway of increased activity in resistant cells, or
an effect upon influx of the cytotoxic agent or upon its
cytosolic binding. Among the many drugs studied which
demonstrate such a modifying action verapamil has been
most frequently used. It has been shown to reduce resistance
to a wide variety of cytotoxic drugs in many tumour cell
lines.
We have previously reported a method of quantifying
resistance to vincristine in primary solid tumour tissues using
a morphological method which generates the post-metaphase
index (PMI) (Ince et al., 1985). By applying this technique to
human colonic carcinoma tissue grown in organ culture we
have shown that verapamil increases the degree of metaphase
arrest induced by vincristine (Ince et al., 1986).
In the present communication we have proceeded to
investigate the extent to which verapamil-enhanced sensi-
tivity to vincristine can be demonstrated by this morpho-
logical method in intact experimental animals. We report
here data from two experiments performed in vivo on
intestinal tumours induced by chemical carcinogenesis in
rats. The first is a study of the effect of high dose verapamil
on the sensitivity of tumour and normal mucosa to vin-
cristine, over a range of doses. The second is a verapamil
dose-response experiment performed at a single dose of
vincristine. The results confirm enhanced resistance to
vincristine of tumour tissue over normal mucosa and
indicate a sensitising effect of verapamil in vivo.
Materials and methods
Rats and DMH-treatment schedules
Eighty-eight male Wistar rats (Olac Ltd, Bicester) were used
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in the two experiments. They were maintained throughout
the experiment with unrestricted access to food (Breeders
diet no. 3, Special Diet Services Ltd, Witham) and tap water.
They were housed in a 12h light/dark cycle, and all
injections were administered between 0900h and 1100h. All
the animals received a long-term, low-dose schedule of 1,2-
dimethylhydrazine (Aldrich Chemical Co. Ltd, Poole)
exposure, comprising 24 subcutaneous injections at one week
intervals, of a dose of 15mg (base)kg-1 body weight. The
animals were aged between 6 and 10 weeks at the start of
the DMH treatment schedule and weighed between 150 g
and 220g. At the time of PMI experiments they were aged
between 34 and 39 weeks and weighed between 350 g and
550g. The animals were left for a period of between 3 and 5
weeks after the last DMH injection before subsequent experi-
mentation. We adopt this procedure to allow complete
recovery from any acute toxic effects of DMH.
High dose verapamil experiment (experiment 1)
Twenty-six verapamil-treated animals all received verapamil
(Abbott Laboratories, Queensbourough) at a dose of
100 mg kg- 1 body weight, administered by intraperitoneal
injection in a vehicle comprising ethanol 40% v/v in normal
saline. Thirty-four control (i.e. verapamil-untreated) animals
received an intraperitoneal injection of the same volume of
the vehicle only. Vincristine (Oncovin, Eli Lilly Ltd,
Basingstoke) was administered at one of the following doses;
0.5, 0.25, 0.1, 0.05, 0.01 mgkg-1 body weight, by i.p. in-
jection. The drugs were administered in the following
sequence: verapamil was administered 2 h prior to vincristine,
and the animals were killed 2 h after vincristine injection.
Thus the animals received verapamil or vehicle alone for 4 h,
and vincristine in combination for the last two hours. This
experimental protocol generates 10 permutations of drug
administration (5 vincristine doses given either with or
without verapamil). The animals were assigned to one of
these 10 groups by a method adopted to optimise the
distribution of colonic tumours between the groups. The
experiment was performed in small batches selected at
random sequentially over a number of days, with dissection
of the colons to maintain a running total of tumours in each
group. This procedure allowed the allocation of animals on
subsequent days to groups where fewer tumours were
present. A target of 6 colonic tumours in each group was
achieved in 8 of the 10 groups.
The animals were killed by cervical dislocation and
autopsy was performed immediately. The small bowel was
dissected free and fixed unopened for at least 10 h in
Carnoy's fluid. The colon was dissected free with a margin
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of anal skin, opened along its length, and pinned to a cork
board prior to Carnoy fixation. The tissues were
subsequently transferred to cellosolve. Following fixation the
specimens were carefully examined for tumours. Transverse
blocks of the bowel were taken through each tumour, and
through non-neoplastic mucosa at two sites prone to tumour
development, viz. 20mm distal to the pylorus, and at the
junction of the middle and distal thirds of the colon. All
these blocks were processed routinely to paraffin wax;
histological sections prepared at 4pm were stained with
haematoxylin and eosin prior to counting.
Verapamil dose response experiment (experiment 2)
Twenty-eight animals received verapamil at one of the
following doses; 100, 50, 25, 10, and 5mg kg- 1 body weight.
All the animals received vincristine at a single dose of
0.1 mg kg-1 body weight. Otherwise the experiment was
performed exactly as above.
Counting procedures and statistical analysis
The proportion of mitotic figures showing escape from
metaphase arrest in each section of tumour or normal
mucosa was obtained using the method that we have
previously described (Ince et al., 1985). The histological
sections were counted as follows: whole circumferential
sections of non-neoplastic mucosa were counted for the low
doses of vincristine, and half or one third circumferences for
the higher dose groups where metaphase arrest was more
complete and mitotic figures thus much more numerous.
Total number of mitotic figures was obtained, together with
the total of unequivocally normal post-metaphase figures.
The morphology of prophase is difficult to define, and it was
decided to exclude this phase of mitosis from the study,
although late prophase figures may have been included in
the overall total. Using the counting method described the
number of all mitoses counted in each section was 100-200
for low dose groups and 200-300 for high dose groups. In
the case of tumours, areas of viable neoplastic tissue were
selected at hazard and similar counts made. The total
mitoses counted for each tumour was 100-300. In the
subsequent analysis the total mitoses are designated 'm' and
total normal post-metaphase figures 'a'.
The ratio of post-metaphase figures to all mitoses is the
Post-Metaphase Index (PMI = a/m). The relationship
between the PMI, which is an index of the degree of escape
from metaphase arrest, and the dose of vincristine was
analysed using the computer program GLIM (Baker &
Nelder, 1978). The PMI was transformed to the logit;
logit PMI = loge (PMI)
(m -a)
=loge (a)
We selected the logit transformation rather than a simple
logarithmic transformation because of the nature of the
observations. Thus for each observed mitotic figure there are
two 'all or nothing' options viz. metaphase or post-
metaphase. This yields data in the form of a biological assay
with quantal responses for which one possible
transformation is the logistic (Finney, 1978). We found that
this transformation together with transformation of
vincristine dose to log1o dose, was the most satisfactory in
order to linearise our data. These transformed data were
plotted and the slopes of the fitted lines calculated by the
computer model using the method of maximum likelihood
(McCullagh & Nelder, 1983). The data for small bowel and
large bowel were analysed separately; at both sites there are
two tissues represented comprising DMH-treated non-
neoplastic mucosa, and tumour. These were designated
Mucosa and Tumour respectively. Analysis of deviance was
performed in experiment 1 to test for differences between the
slopes and positions of the fitted lines. The t-test was used
based on this analysis to test for significant differences
between the tissues, the sites, and between verapamil-treated
and untreated tissues.
Results
Experiment I
The distribution of tumours and animals bearing tumours
among the experimental groups is shown in Table I. Al-
together 125 tumours were identified, 71 in the colon and 54
in the small bowel. The same range of tumour morphology
was observed as that seen previously in DMH-treated rats
(Sunter et al., 1978), but all the variants were analysed
together.
The mean PMI for each combination of state and tissue at
each dose of vincristine, with or without verapamil, together
with the standard error is shown in Table II. The data show
a progressive rise in metaphase escape (an increasing PMI)
as the dose of vincristine administered decreases. This
corresponds with our previous experience of this kind of
data (Ince et al., 1985; 1986). In 15 of the 20 pairs of data
(verapamil-treated vs. verapamil-untreated) there is less
metaphase escape (i.e. a lower PMI) in the verapamil treated
tissues. The dose-response relationship both in the presence
and absence of verapamil is not linear. In order to test for a
statistically significant difference between these dose response
curves the data were transformed to linearity using the
transformations of logit PMI and logl0 dose as previously
described. Figure 1 shows the transformed data points for
one combination of tissue and treatments, viz. colon -
tumours - verapamil, together with the fitted line calculated
by the computer model. The fitted lines for all the
transformed data are shown in Figures 2 and 3. We have
plotted the negative logit PMI simply because we prefer to
consider the phenomenon in terms of increasing metaphase
arrest plotted against increasing vincristine dose.
Lines were fitted for the four highest doses of vincristine
only. This is because of the minimal degree of metaphase
arrest present at the lowest dose (see Figure 1). The fitted
lines representing verapamil treated tissue lie parallel to the
untreated. At the lowest dose of vincristine this relationship
changes because the degree of escape from metaphase arrest
is virtually maximal at this dose. Thus the PMI for
0.01 mgkg-' vincristine is insufficiently different from the
'native' PMI for an enhancing effect to occur. The figures
show that for both tumour tissue and non-neoplastic
mucosa, in both sites, the fitted lines for the verapamil-
treated tissues lie above their control counterparts. These
differences are not marked and, when tested taking each pair
individually, do not achieve statistical significance. However,
the GLIM program was used to generate the following
mathematical function which summarises the whole of the
data:
-logit PMI=11.50+0.39 if small bowel
-5.36 if tumour
+0.36 if verapamil
+(6.50-3.46 if tumour) x log1o dose
In addition the program generates standard errors of these
parameters allowing simple significance testing as follows:
parameter
small bowel
tumour
tumour (slope)
verapamil
s.e. df t value
0.39 0.15 26
- 5.36 1.33 26
-3.46 1.08 26
0.36 0.16 26
t=2.53
t= 4.02
t=3.20
t=2.21
P<0.05
P<0.001
P<0.01
P<0.05
This analysis uses the whole of the data together and
shows significant reduction in vincristine resistance in the
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Table I Distribution of intestinal tumours and of tumour bearing animals in experiment 1 by anatomical
site, and verapamil and vincristine dosage group
a. No. of animals
b. No. of animals with tumours
Anatomical site Verapamil c. No. of tumours
Vincristine dose (mgkg-1 body weight)
0.5 0.25 0.1 0.05 0.1 (Total)
a b c a b c a b c a b c a b c a b c
Colon treated 6 5 6 3 3 9 6 4 9 5 2 6 9 4 5 29 18 35
untreated 4 4 8 6 4 7 8 6 8 7 5 10 9 3 3 34 22 36
Small intestine treated 6 3 5 3 2 3 6 3 4 5 2 2 9 6 9 29 16 23
untreated 4 2 3 6 4 6 8 5 8 7 4 7 9 5 7 34 20 31
Table II Effect of vincristine dose on the PMI% in the presence or absence of verapamil in each site/tissue
combination. Standard errors are included in parenthesis and were calculated by the method of Snedecor and
Cochran (1971)
PMI%
Colon Small intestine
tumour mucosa tumour mucosa
Vincristine
dose (mgkg 1) treated untreated treated untreated treated untreated treated untreated
0.0 16.0 15.0 16.8 18.5
(1.2) (1.7) (2.5) (2.1)
0.1 11.5 15.5 9.5 11.3 14.2 13.8 8.1 7.8
(1.3) (2.4) (1.8) (1.6) (1.9) (2.1) (2.0) (3.1)
0.05 8.2 10.5 4.4 4.5 3.8 6.5 3.3 2.3
(1.4) (1.5) (1.5) (2.2) (0.2) (2.5) (1.5) (1.4)
0.10 2.9 3.1 0.3 0.9 1.1 5.1 0.2 0.4
(0.9) (1.2) (0.1) (0.5) (0.4) (0.1) (0.1) (0.3
0.25 0.8 1.7 0.2 0 0.1 1.0 0 0.1
(0.3) (0.9) (0. 1) (0. 1) (0.5) (0. 1)
0.5 0.2 0.5 0 0 0.5 0.2 0 0
(0. 1) (0.2) (0.4) (0. 1)
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Figure 1 Experiment 1 colon - tumours - verapamil. The data
points and fitted line for one combination of tissue and
treatment. The circles and arrows represent PMI values of 0 (i.e.
logit PMI = - oo). The lowest dose of vincristine (0.01) shows
PMI values approaching that of a group of verapamil only
controls. This latter group has been transposed to the right hand
side for clarity. The dotted section of the line represents an
extrapolation from the line fitted between 0.05 and 0.5
(log,0 mgkg- body wt.) at lower doses of VCR. It clearly does
not correspond to the data over this dose range.
presence of verapamil at an administered dose of
100mgkg-1 (P<0.05). In addition the data confirm our
previously reported findings of relative vincristine resistance
in the colon compared with the small bowel (P<0.05), and
in tumour tissue compared with normal mucosa (P<0.OO1).
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Figure 2 Experiment 1 - colon. All 4 fitted lines for verapamil
treated (-----) and control ( ) tissues. The higher the position
of a line the greater the degree of metaphase arrest, i.e. the
greater the sensitivity to vincristine.
Experiment 2
The distribution of intestinal tumours between the verapamil
dose groups is shown in Table III. A total of 75 tumours
were identified and a goal of 7 colonic tumours per dose
group was achieved in 3 of the 5 groups. As previously
described all morphological groups of tumours were
analysed together.
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Figure 3 Experiment 1 - small intestine. As Figure 2, verapamil-
treated (-----) and control ( ) tissues.
The mean PMI% for tumours at each dose of verapamil is
shown in Table IV. At this dose of vincristine (0.1 mg kg-1)
there is only minimal escape from metaphase arrest in non-
neoplastic mucosa and this tissue was excluded from the
analysis. The mean PMI% for the tumour tissues in this
experiment at the verapamil dose given in the first
experiment are 1.9 in the colon and 1.2 in the small bowel,
and they are not significantly different from the values for
the same vincristine dose (verapamil-treated) in experiment 1
of colon 2.9, and small bowel 1.1. We examined the data
using the mathematical transformation as described above to
look for a significant decrease in escape from metaphase
arrest with increasing dose of verapamil. This is illustrated in
Figures 4 and 5. The individual data points are included as
well as the fitted lines. The fitted lines illustrated are curved
because the abscissa plots the untransformed PMI%. The
fitted line for colonic tumours shows the expected effect, that
for small bowel tumours shows an apparent reversal of this
trend. The equations describing these lines are as follows:
colon logit PMI= -2.98-0.74x log dose
small bowel logit PMI =-4.36 + 0.23 x log dose
Using analysis of deviance standard errors for the slopes of
the lines were calculated as follows:
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Figure 4 Experiment 2 - colon. Data points and fitted lines for
tumour tissue. The ordinate shows the untransformed PMI thus
the fitted line appears curved. The negative slope of the line is
significantly different from 0 (P<0.05).
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Figure 5 Experiment 2 - small intestine. Data points and fitted
line for tumour tissue. The ordinate shows the untransformed
PMI thus the fitted line appears curved. The positive slope is not
significantly different from 0 (P>0.05).
s.e. df t value
-0.74 -0.35 29 2.09
0.23 -0.33 28 0.71
P<0.05
NS
Our analysis shows a significant slope of the fitted line for
the colonic tumours but not for small bowel tumours. Thus
we have demonstrated a slight increase in the sensitivity to
vincristine in colonic tumours in the presence of increasing
doses of verapamil. The failure to demonstrate an effect in
small bowel tumours in this experiment may be due to the
rather small amount of data available but, in view of the
negative value for the slope, it probably reflects the lower
level of vincristine resistance present in this tissue.
Discussion
We have previously shown that the PMI offers a
morphological means of measuring the degree of resistance
to the stathmokinetic effect of vincristine within a tissue
(Ince et al., 1985). This method has the advantage over
biochemical methods of estimating parameters related to
drug resistance in intact tissues in that the measurements
made relate exclusively to the epithelial tissue. Our previous
work has also shown that the technique is sensitive enough
in vitro to show differences between the resistance of tumour
tissues when treated with a sensitising agent as compared
Table III Distribution of intestinal tumours and tumour bearing animals in experiment 2 by
anatomical site and verapamil dosage group. All animals received vincristine at 0.1 mg kg1
a. No of animals
b. No. of animals with tumours
Anatomical site c. No. of tumours
Verapamil dose (mgkg-' body weight)
100 50 25 10 5 (Total)
a b c a b c a b c a b c a b c a b c
Colon 5 3 10 6 3 10 5 4 5 6 3 9 6 3 4 28 16 38
Small intestine 5 2 10 6 4 8 5 3 9 6 4 7 6 3 6 28 16 29
parameter
slope-colon
slope-small bowel
---I
1n_)u r,
352 P. INCE et al.
Table IV Effect of verapamil on the PMI% in tumour tissue
at each site at vincristine dose of 0.1 mg kg- 1. Standard errors
are included in parenthesis and were calculated by the method
of Snedecor and Cochran (1971)
PMI%
Verapamil dose (mgkg-1)
Anatomical site 100 50 25 10 5
Colon 1.9 0.8 2.5 2.3 3.4
(0.9) (0.7) (1.4) (2.9) (1.5)
Small intestine 1.2 3.0 1.4 1.4 1.8
(1.0) (2.7) (0.7) (1.0) (0.8)
with control untreated tissue (Ince et al., 1986). In vivo we
have shown differences between normal and neoplastic
tissues and between different regional types of epithelial
tissues in the gut.
The first experiment described here shows that using the
PMI it is possible to show a sensitising effect of verapamil
(P<0.05). It is apparent from the data that this effect is
small. We have shown a similar degree of tumour cell
resistance compared with normal mucosa to that which we
have previously reported. Verapamil does not reduce the
resistance of tumour tissue to that of normal mucosa. The
pharmacokinetics of verapamil are of importance in the
interpretation of the experiment. The administered dose of
100mgkg-1 resulted in the death of 3 animals in the treated
group (-LD1O). This is a high dose and was selected to
ensure the maximum tissue levels compatible with an
adequate survival to the end of the experiment. In clinical
therapy the highest achievable dose of verapamil is roughly
equivalent to 5-10 mg kg-1. In the second experiment re-
ported here this dose range is associated with minimal
enhancement of vincristine sensitivity. Thus it would seem
that an effective clinical application of modifiers will require
compounds active at lower doses.
The data presented here show no distinction between the
effect of verapamil on normal compared with neoplastic
tissues. This may reflect a similar sensitising effect of
verapamil on both tissues, but this remains to be established.
The standard errors of the means are large, particularly so in
experiment 2, and larger numbers of tumours and animals
would be needed to resolve this problem. We are currently
investigating this aspect of the resistance of normal mucosa
using our explant organ culture system. In this context the
high level of mRNA for the p-glycoprotein reported in both
tumourous and normal human colonic tissues is of interest
(Fojo et al., 1987). This finding can be interpreted as
evidence of a naturally occurring cellular mechanism to
protect the colon, amongst other tissues, from the effects of
plant toxins. Taken further the theory can be used to
account for both the enhanced resistance of MDR cells, and
the resistance of spontaneous tumours on the basis of
increased activity of this normal mechanism. Many tissues
show low levels of p-glycoprotein mRNA including
haemopoetic tissue. If modulators can only act on tissues
possessing the p-glycoprotein then the bone marrow should
be spared the effects of enhanced sensitivity. The PMI
technique provides an opportunity to investigate this
therapeutically important point.
In terms of the investigation of the relationship between
the innate resistance of primary solid tumours and the
acquired MDR phenotype we have shown both here in vivo,
and previously in vitro using human tissue (Ince et al., 1986),
that the innate resistance to vincristine of colonic cancer
shares a pharmacological property with MDR, viz.
modulation of resistance by verapamil. Other evidence is
required to elucidate this link. Studies using monoclonal
antisera to the MDR-related p-glycoprotein in patients
relapsing from acute nonlymphoblastic leukaemia have
demonstrated resistant tumour cells containing large
amounts of antigen (Kartner et al., 1985, Ma et al., 1987).
Blot analysis of a wide range of human tissues, both normal
and malignant, has shown higher levels of cytoplasmic m-
RNA coding for p-glycoprotein in adrenal, renal and colonic
tissues compared with others (Fojo et al., 1987). Biochemical
studies have shown decreased drug accumulation in human
tumour cells lines derived from haematological malignancies
(Ferguson & Cass, 1985) and carcinoma tissue (Fojo et al.,
1985). However, there is no evidence concerning the
biochemical activity of the p-glycoprotein in native colonic
tumour cells or in normal colonic mucosa. We are currently
investigating the accumulation, localisation and efflux of
tritiated alkaloids in normal colonic mucosa to compare
these properties with those described in MDR.
Histological sections were prepared by Mrs K. Elliot. Graphs were
prepared by Mr W. Robinson, and secretarial assistance provided by
Miss E. Wark. This study was supported by a grant from the North
of England Cancer Research Campaign.
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